STXS

Stereotaxis, Inc. 2009 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: Stereotaxis, Inc.
Reporting Period: Fiscal year ended December 31, 2009
Business Overview: Stereotaxis designs, manufactures, and markets the Niobe system, an advanced cardiology instrument control system that uses magnetic fields to remotely navigate catheters and guidewires for treating arrhythmias and coronary artery disease. The company also markets the Odyssey Enterprise Solution for lab information management. As of December 31, 2009, the company had recognized revenue on 143 Niobe systems, 37 Odyssey Vision systems, and 6 Odyssey Enterprise Cinema systems.

Key Financial Metrics

Note: Recurring revenue (disposables, service, accessories) increased to 36% of total revenue in 2009, up from 30% in 2008.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 27% year-over-year to $51.15 million. System sales revenue grew 15% to $32.7 million, while recurring revenue from disposables, service, and accessories surged 54% to $18.5 million.
• Profitability Improvement: The net loss narrowed significantly to $27.5 million from $43.9 million in 2008, driven by revenue growth and a reduction in operating expenses.
• Expense Reduction: Research and Development (R&D) expenses decreased 18% to $14.3 million. General and Administrative (G&A) expenses dropped 29% to $15.0 million, largely due to the absence of one-time CEO retirement expenses and investment impairments recorded in 2008.
• Geographic Shift: International revenue grew substantially to $28.8 million (56% of total), compared to $11.3 million in 2008, while U.S. revenue declined to $22.3 million.
• Financing Activity: The company raised approximately $27.8 million in net proceeds from a public offering of common stock in October 2009.

Guidance, Outlook, and Risks

Outlook and Commentary: Management expects to incur additional losses in 2010 as it continues product commercialization and R&D. The company anticipates that sales and marketing expenditures will increase in 2010. While existing cash and borrowing facilities are believed sufficient to fund operations for the next 12 months, the company may require additional financing.

Key Risks and Contingencies:

• Profitability: The company has incurred cumulative net losses of approximately $323 million since inception and may never achieve profitable operations.
• Liquidity: Continued dependence on equity financing or debt to fund operations; failure to raise capital could force delays in development or commercialization.
• Collaborations: Significant reliance on strategic alliances with Siemens, Philips, and Biosense Webster for integration, distribution, and co-development. Failure of these partnerships could materially impact revenue.
• Regulatory and Reimbursement: Risks associated with obtaining FDA/CE approvals for new devices and potential changes in third-party payer reimbursement policies.
• Backlog Uncertainty: Backlog consists of purchase orders subject to contingencies, construction delays, and potential cancellations.

Investor Verification Checklist

• Recurring Revenue Sustainability: Verify the growth trajectory of disposable device sales and service contracts, which now comprise over one-third of revenue.
• Backlog Conversion: Assess the likelihood of converting the $37 million backlog into recognized revenue, considering the 18-month recognition window and potential for order cancellations.
• Debt Covenants: Review compliance with the "tangible net worth" covenants in the revolving credit agreement and the repayment terms of the Biosense Webster advance ($13.3 million outstanding).
• International Exposure: Evaluate the risks associated with the shift to 56% international revenue, including currency fluctuations and foreign regulatory environments.
• Capital Requirements: Confirm the sufficiency of the $30.5 million cash balance and $5.9 million remaining borrowing capacity to fund operations through 2010 without dilutive equity raises.